| CEO Name | Mark J. Foley |
| Nationality | United States |
| Net Worth Estimation | $30 million |
Mark J. Foley's estimated net worth of around $30 million stems from his compensation as CEO of Revance Therapeutics, substantial holdings of company stock, and two decades of executive leadership across biotech and medical technology companies. SEC filings reveal significant option exercises and share ownership, contributing to his multimillion-dollar portfolio.
Mark J. Foley, CEO of Revance Therapeutics in the biotechnology sector, has an estimated net worth of $30,000,000. His net worth represents 28.5% of the maximum and 300% of the minimum estimated CEO net worths in this category.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Mark J. Foley Performance in Revance Therapeutics
Mark J. Foley, CEO of Revance Therapeutics, demonstrates strong leadership by driving innovative strategies and operational excellence. His decisive decision-making has accelerated product development and expanded market presence, notably enhancing the company's competitive edge in aesthetics and neuromodulators. Under Foley's performance-focused guidance, Revance achieved significant revenue growth and strengthened its position as a key player in the biopharmaceutical industry.
Latest News
Revance Therapeutics Announces CEO Transition and Strategic Growth Plans
Revance Therapeutics has appointed Nadeem Moiz as its new CEO, succeeding founder Jeff Bedard who transitions to Executive Chairman, as part of a strategic leadership succession following Crown Laboratories' acquisition. The move aims to strengthen operational efficiency and drive innovation in the aesthetics and skincare sector.
Source: http://www.prnewswire.com/news-releases/revance-expands-leadership-team-with-key-executive-appointments-302572420.html